Loading patent…
AssigneeVertex Pharmaceuticals Incorporated
InventorsWilliam Rowe, Patricia Hurter, Christopher R. Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi, Gregor Zlokarnik, Fredrick F. Van Goor
Estimating the term…
The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
A method of treating or lessening the severity of Osteoporosis or Osteopenia in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.
A method of providing bone healing and/or bone repair in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.
A method of treating or lessening the severity of COPD, smoke induced COPD, or chronic bronchitis in a patient comprising administering to said patient Compound 1 or a pharmaceutically acceptable salt thereof.
A method of treating or lessening the severity of cystic fibrosis in a patient comprising administering a pharmaceutical composition to the patient, in which the pharmaceutical composition comprises about 34.1 wt % of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt % of substantially amorphous or amorphous Compound 1 by weight of the dispersion, about 19.5 wt % of HPMCAS by weight of the dispersion, and about 0.5 wt % SLS by weight of the dispersion;
A method of treating or lessening the severity of cystic fibrosis in a patient comprising administering a pharmaceutical composition to the patient, in which the pharmaceutical composition comprises about 34.1 wt % of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt % of substantially amorphous or amorphous Compound 1 by weight of the dispersion, about 19.5 wt % of HPMCAS by weight of the dispersion, and about 0.5 wt % SLS by weight of the dispersion;
A pharmaceutical composition comprising a solid dispersion of substantially amorphous or amorphous Compound 1 and HPMCAS, wherein the solid dispersion comprises up to about 1 mg of substantially amorphous or amorphous Compound 1.
A pharmaceutical composition comprising a solid dispersion of substantially amorphous or amorphous Compound 1 and HPMCAS, wherein the solid dispersion comprises up to about 5 mg of substantially amorphous or amorphous Compound 1.
A pharmaceutical composition comprising a solid dispersion of substantially amorphous or amorphous Compound 1 and HPMCAS, wherein the solid dispersion comprises about 15 mg of substantially amorphous or amorphous Compound 1.
Dependencies are inferred from the claim text.